Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.42 |
| ▸ | PPARG | P37231 | 12/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358157 | 0.90 | PPARA (0.44) | PPARAPPARGLMNACNR1CNR2 | |
| SCHEMBL5358817 | 0.87 | PPARG (0.41) | PPARAPPARGLMNACNR1CNR2 | |
| SCHEMBL5364092 | 0.87 | PPARG (0.41) | PPARAPPARGLMNACNR1CNR2 | |
| SCHEMBL5356946 | 0.81 | PPARA (0.46) | PPARAPPARGLMNAPPARD | |
| SCHEMBL5364241 | 0.81 | PPARG (0.43) | PPARAPPARGPLA2G10PLA2G2APLA2G5 | |
| SCHEMBL5364820 | 0.80 | PPARG (0.51) | PPARAPPARGPLA2G10PLA2G2APLA2G5 | |
| SCHEMBL5353991 | 0.80 | PPARG (0.45) | PPARAPPARGLMNACNR1CNR2 | |
| SCHEMBL5364836 | 0.76 | HPGD (0.46) | PPARAPPARGCNR1CNR2MEN1 | |
| SCHEMBL17186715 | 0.74 | PPARA (0.43) | PPARAPPARGLMNAGAAMCOLN3 | |
| SCHEMBL5358807 | 0.73 | CNR1 (0.46) | PPARAPPARGCNR1CNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | claimed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | claimed |
| US-7220880-B2 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111406-A1 | Amide linker peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885LMNA 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.